9月29日 - ** Pyxis Oncology（PYXS.O）股价在盘后交易中下跌4.5%，报2.77美元，该公司正寻求股权融资
** 总部位于马萨诸塞州波士顿的PYXS (link) 开始发行股票和预先注资认股权证，以及配套认股权证
** 该公司计划将募集资金净额用于推进其领先的临床候选药物——micvotabart pelidotin（MICVO），这是一种用于治疗实体瘤的抗体药物偶联物，同时用于补充营运资金及一般用途
** 利林克合伙公司（Leerink Partners）、古根海姆（Guggenheim）和富国银行（Wells Fargo）担任联合簿记管理人
** PYXS 目前流通股约为 8,340 万股，市值约为 2.42 亿美元
** 该股周二收盘持平于2.90美元，但年初至今已上涨152%
** 据伦敦证券交易所集团（LSEG）数据显示，10位分析师中有9位给予该股“强烈买入”或“买入”评级，1位给予“持有”评级；目标价中位数为7美元
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.